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ABSTRACT

Prostasin protein has been found to be a useful marker for
determination of the invasiveness of and as a means to treat
human carcinomas. Using RT-PCR and western blot
analyses, prostasin protein and mRNA expression were
found in normal human prostate epithelial cells and the
human prostate cancer cell line LNCaP, but not in the highly
invasive human prostate cancer cell lines DU-145 and PC-3.
Imunohistochemistry studies of human prostate cancer
specimens revealed a down-regulation of prostasin in highgrade tumors. Using RT-PCR and western blot analyses,
prostasin protein and mRNA expression were found in a
non-invasive human breast cancer cell line, MCF-7, while
invasive human breast cancer cell lines MDA-MB-231 and
MDA-MB-435s were found not to express either the prostasin protein or the mRNA. A non-invasive human breast
cancer cell line. MDA-MB-453, was shown to express
prostasin mRNA but not prostasin protein. Transfection of
DU-145 and PC-3 cells with a full-length human prostasin
cDNArestored prostasin expression and reduced the in vitro
invasiveness by 68% and 42%, respectively. Transfection of
MDA-MB-231 and MDA-MB-435s cells with a full-length
human prostasin cDNA restored prostasin expression and
reduced the in vitro invasiveness by 50% for either cell line.
6 Claims, 7 Drawing Sheets
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[Review] [102 refs] Human Pathology, 23(3):211-22,
1992), for which no effective treatment exists (Yagoda A,
TREATING INVASIVE CARCINOMAS
Petrylak D. Cytotoxic chemotherapy for advanced hormoneresistant prostate cancer, [Review] [63 refs] Cancer. 71(3
This invention relates to prostasin and its use in the
diagnosis and treatment of prostate and breast cancers, and 5 Suppl): 1098-109, 1993 and Petrylak, 1993). Of the remaining 50% cases, 1/3 (-50,000) are diagnosed as organ-confined
is a divisional application to U.S. application Ser. No.
but micrometastasis may be present. The final group of
09/755,811 filed on Jan. 5, 2001, now U.S. Pat. No. 6,569,
patients (-100,000) have truly organ-confined prostate can684, which claims the priority to U.S. Provisional Applicacer and can be cured by radical prostatectomy (Sgrignoli A
tion Ser. No. 60/174,801 filed Jan. 6, 2000 and was supR Walsh P C, Steinberg G D, Steiner M S, Epstein J I.
10
ported in part by Department of Defense Prostate Cancer
Prognostic factors in men with stage D 1 prostate cancer:
Research Grant DAMD17-98-l-8590, and in part by grants
identification
of patients less likely to have prolonged surto principal investigator K. X. CHAI from the Florida
vival after radical prostatectomy [see comments]. Journal of
Hospital Gala Endowed Program for Oncologic Research.
Urology, 152(4):1077-81, 1994; Zincke H, Oesterling J E,
BACKGROUND AND PRIOR ART
15 Blute NL, Bergstralh E J, Myers RP, Barrett D M, long term
(15 years) results after radical prostatectomy for clinically
For men in the U.S., prostate cancer is the most comlocalized (stageT2c or lower) prostate cancer [see
monly diagnosed cancer, and the second leading cause of
comments]. Journal of Urology, 152(5 Pt 2): 1850-7, 1994)
cancer-related death (Greenlee R T, Murray T, Bolden S,
or left untreated (watchful waiting) without the risk of
Wingo PA Cancer statistics, 1999. Ca: a Cancer Journal for
Clinicians 2000:50:7-33). Prostate cancers originate as 20 life-threatening or life-altering. For the patients with nonorgan-confined prostate cancers (discovered via either
localized lesions; some of these localized lesions will
biopsy or surgery), undergoing systemic treatment early is
progress to become invasive, migratory and metastatic. Our
essential to the management of their cancer (Yagoda A,
current understanding of the mechanisms of the prostate
Petrylak D. Cytotixic chemotherapy for advanced hormonecancer invasion process, however, is poor. Our ability to
predict the acquisition of invasive potentials by a prostate 25 resistant prostate cancer [Review] [ 63 refs] Cancer, 71(3
Suppl): 1098-109, 1993). Consequently, it will be ideal,
cancer is limited.
both medically and economically, if one could precisely
The mechanisms leading to the development of a prostate
predict upon early pathological examination of the tumor,
cancer are complex. Currently, it is believed to be the result
which group of patients will have truly organ-confined
of multiple transformation steps from normal prostate glandular cells (Carter H B, Piantadosi S, Isaacs J T. Clinical 30 disease versus which group will have invasive prostate
cancer.
evidence for and implications of the multistep development
Clinical staging of prostate cancer generally depends on
of prostate cancer. Journal of Urology, 143(4):742-6, 1990).
the results of three tests that are performed in the following
The initial steps result in what are described as prostatic
order: a PSA (prostate-specific antigen) blood test as a
interepithelial neoplastic (PIN) lesions (Isaacs J T, Molecular markers for prostate cancer metastasis. Developing diag- 35 screening method; DRE (digital rectal examination) for an
initial indication of palpable disease; and, a biopsy to obtain
nostic methods for predicting the aggressiveness of prostate
samples for histological examination. Prostate cancers,
cancer. [Review] [92 refs] American Journal of Pathology,
removed either via biopsy or surgery, are graded histologi150(5):1511-21, 1997). These PIN lesions may then typically by the system of Gleason. (Gleason D F, Classification
cally have three different fates based on an assessment of
their impact to the patient. The PIN lesions can remain as 40 of prostatic carcinomas. Cancer Chemotherapy ReportsPart 1, 50(3):125-8, 1966), which is an evaluation of how
such, not producing histologically detectable prostate
aggressive and how poorly-differentiated the prostate cancancer, or further transform into histologically detectable
cers are. The aggressiveness of prostate tumors: of low
prostate cancer. Most of the histologically detectable prosGleason scores ( <5) is limited; of high Gleason scores
tate cancers will be asymtomatic in the patient and remain
non-manifest clinically as many are discovered post-mortem 45 (8-10) are highly aggressive; but, for the intermediate
Gleason-score (5-7) prostate cancers (76% of prostate
(Carter H Coffey D, Prostate Cancer: the magnitude of the
tumors), the accuracy of predicting their aggressiveness is
problem in the United States. In a Multidisciplinary Analysis
poor (Gleason D F, Mellinger GT. Prediction of prognosis
of Controversies in the Management of Prostate Cancer.
for prostatic adenocarcinoma by combined histological
(Eds. Coffey D, Resnick M, Door R, et al.), pp 1-9, Plenum
Press a 1988; Carter H B Piantadosi S, Issacs J T, Clinical 50 grading and clinical staging, Journal of Urology, 111(1):
58-64, 1974). Thus, the ability to accurately determine the
evidence for implications of the multistep development of
aggressiveness of these intermediate Gleason-score prostate
prostate cancer, Journal of Urology, 143(4):742-6, 1990;
tumors has remained as a practical challenge to, and a
Scardino P T, Weaver R, Hudson M A Early detection of
primary goal for, prostate cancer research (Isaacs J T,
prostate cancer. [Review] [102 refs] Human Pathology,
23(3):211-22, 1999). Prostate cancers are diagnosed clini- 55 Molecular markers for prostate cancer metastasis. Developing diagnostic methods for predicting the aggressiveness of
cally by an estimate of size and location using the TNM
prostate cancer. [Review] [92 refs] American Journal of
staging system (Denis L J, Staging and prognosis of prostate
Pathology, 150(5): 1511-21, 1997). Especially with regard to
cancer. European Urology, 24 Suppl 2:13-8, 1993), and by
the number of patients (150,000) facing a decision of
pathological staging based on an examination of the histology of the removed prostate via either biopsy or prostatec- 60 whether to undergo systemic treatment, the most urgent
demand in prostate cancer care is the development of
tomy using a system by D. F. Gleason, (Gleason D F,
methods to enhance our ability to accurately predict the
Classification of prostatic carcinomas. Cancer Chemoaggressiveness of the tumors with Gleason scores of 5-7.
therapy Reports-Part 1, 50(3):125-8, 1966). About 50% of
prostate cancer cases receiving treatment are diagnosed
It is now commonly believed that cancers occur via
clinically as advanced, or, non-organ-confined (Scardino P 65 multiple transformation steps by accumulating mutations in
T, Weaver R, Hudson M A. Early detection of prostate
three classes of genes: proto-oncogenes (Park M, Oncogenes. In The Genetic Basis of Human Cancer (Eds. Vogelcancer.
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stein B and Kinzler KW), pp205-28. McGraw-Hill Health
Umbas R, Isaacs W B, Bringuier P P, Schaafsma H E,
Professions Divisions, 1998); tumor-suppressor genes
Karthaus H F, Oosterhof G 0 Debruyne F M, Schalken J A,
(Knuutila S, Aalto Y, Bjorkqvist AM, EL-Rifai W, Hemmer
Decreased E-cadherin expression is associated with poor
S, Huhta T, Kettunen E, Kiuru-Kuhlefelt S, Larramendy M
prognosis in patients with prostate cancer. Cancer Research,
L, Lushnikova T, Manni 0, Pere H, Tapper J, Tarkkanen M, 5 54(14):3929-33, 1994); ~ic integrin (Fornaro M, Tallini G,
Varis A, Wasenius V M, Wolf M, Zhu Y, DNA copy number
Bofetiado CJ, Bosari S, Languino LR. Down-regulation of
losses in human neoplasms. [Review] [197 refs] American
~ic integrin, an inhibitor of cell proliferation, in prostate
Journal of Pathology, 155(3):683-94, 1999); and, DNA
carcinoma. American Journal of Pathology, 149(3):765-73,
repair genes (Knuutila S, Aslto Y, Bjorkqvit AM, EL-Rifai
1996Fornaro M, Manzotti M, Tallini G, Slear AE, Bosari S,
W, Hemmer S, Huhta T, Kettunen E, Kiuru-Kuhlefelt S, 10 Ruoslahti E, Languino LR. ~lC integrin in epithelial cells
Larramedy ML, Lushnikova T, Manni 0, Pere H, Tapper J,
correlates with a nonproliferative phenotype: forced expresTarkkanen M, VarisA, Wasenius V M, Wolf M, Zhu Y. DNA
sion of ~1 C inhibits prostate epithelial cell proliferation.
copy number losses in human neoplasms. [Review] [197
American Journal of Pathology. 153(4):1079-87, 1998; p27
refs] American Journal of Pathology, 155(3):683-94, 1999).
(kipl) (Tsihlias J, Kapusta LR, DeBoer G, Morava-Protzner
The histological prostate cancers for which the prediction of 15 I, Zbieranowski I, Bhattacharya N, Catzavelos G C, Klotz L
clinical aggressiveness is difficult (those with the intermeH, Slingerland JM, Loss of cyclin-dependent kinase inhibidiate Gleason scores 5-7) probably have not gone through
tor p27Kipl is a novel prognostic factor in localized human
the necessary "multi-step" transformation to acquire the
prostate adenocarcinoma. Cancer Research, 58(3):542-8,
potentials to behave aggressively (as would the high-grade
1998); and CD44 (Lou W, Krill D, Dhir R, Becich M J, Dong
cancers). This notion was supported by studies comparing 20 J T, Frierson H F Jr. Isaacs W B, Isaacs J T, Gao A C.
the course of prostate cancer development among men in
Methylation of the CD44 metastasis suppressor gene in
Japan and in the U.S., and Japanese men who migrated to the
human prostate cancer. Cancer Research, 59(10):2329-31,
U.S. (Carter H B, Piantadosi S, Isaacs J T. Clinical evidence
1999). By using the method of immunohistochemistry, these
for and implications of the multistep development of prosgenes were found to be down-regulated in prostate cancer.
tate cancer. Journal of Urology, 1990; Haenszel W, Kurihara 25 KAI's down regulation is a potential predictor of metastasis
M, Studies of Japanese Migrants, I. Mortality form cancer
(Dong, et al., 1996: Ueda et al., 1996). While E-cadherin's
and other diseases among Japanese in the United States.
down regulation is strongly correlated to higher Gleason
Journal of the National Cancer Institute,40(1):43-68, 1968:
grades. Functional studies of these genes have given clues to
Akazaki K, Stemmerman G N. Comparative study of latent
their role in prostate cancer or normal prostate biology.
carcinoma of the prostate among Japanese in Japan and 30 (Debruyne F M, Isaacs W B, Expression of the cellular
Hawaii. Journal of the National Cancer Institute. 50(5):
adhesion molecule E-cadherin is reduced or absent in high1137-44, 1973; Dunn J E, Cancer epidemiology in populagrade prostate cancer. Cancer Research, 52(18):5104--9,
tions of the United States-with emphasis on Hawaii and
1992; Umbas R, Isaacs W B, Bringuier PP, Schaafsma HE,
California-and Japan. Cancer Research, 35( 11 Pt.2):
Karthaus H F, Oosterhof G 0 Debruyne F M, Schalken J A
3240-5, 1975). The findings were that first- and second- 35 Decreased E-cadherin expression is associated with poor
generation Japanese men who migrated to the U.S. have a
prognosis in patients with prostate cancer. Cancer Research,
higher prostate cancer incident rate than native Japanese
54(14):3929-33, 1994; metastasis suppressor gene during
men. The emigrant Japanese men's prostate cancer incident
the progression of human prostatic cancer infrequently
rate is similar to that of men in the U.S. Investigating the
involves gene mutation or allelic loss. Cancer Research,
changes of expression in these three classes of cancer- 40 56(19):4387-90; 1996 Ueda T, Ichikawa T, Tamaru J,
relevant genes during the course of prostate cancer develMikata A, Akakura K, Akimoto S, Imai T, Yoshie 0,
opment will lead to a better understanding of the processes
Shiraishi T, Yatani R, Ito H, Shimazaki J. Expression of the
by which prostate cancers acquire their aggressive potenKAil protein in benign prostatic hyperplasia and prostate
tials. The discovery of molecules whose changes can be
cancer. American Journal of Pathology, 149(5):1435-40,
correlated to the staging of prostate cancer will provide new 45 1996) while E-cadherin's down-regulation is strongly cortools to improve our ability to better predict the aggressive
related to higher Gleason grades (Umbas R, Schalken J A,
behaviors of prostate cancer. This approach is now comAalders T W, Carter B S, Karthaus H F, Schaafsma H E,
monly referred to as "molecular staging".
Debruyne F M, Isaacs W B. Expression of the cellular
adhesion molecule E-cadherin is reduced or absent in highDown-regulated genes such as tumor suppressors, invasion suppressors or metastasis suppressors may be used as 50 grade prostate cancer. Cancer Research, 52(18):5104--9,
prostate cancer markers. Examples of these genes that can
1992; Umbas R, Isaacs W B, Bringuier PP, Schaafsma HE,
potentially serve as prostate cancer markers for "molecular
Karthaus HF, Oosterhof G 0, Debruyne FM, Schalken J A
staging" are: KAil (Dong J T, Suzuki H, Pin S S, Bova G
Decreased E-cadherin expression is associated with poor
S., Schalken J A, Issacs W B, Barrett J C, Issace I T,
prognosis in patients with prostate cancer. Cancer Research,
Down-regulation of the KAll metastasis suppressor gene 55 54(14):3929-33, 1994) Functional studies of these genes
during the progression of human prostatic cancer infrehave given clues to their role in prostate cancer or normal
prostate biology. Human KAI suppress metastasis of rat
quently involves gene mutation or allelic loss. Cancer
Research, 56(19): 4387-90, 1996); (Ueda T, Ichikawa T.,
prostate cancer cells upon gene transfer (Dong J T, Lamb P
W, Rinker-Schaeffer C W, Vukanovic J, Ichikawa T, Isaacs
Tamaru j, Mikata A, Akakura K, Akimoto S, Imai T, Yoshie
0, Shiraishi T, Yatani R, Ito H, Shimazaki J., Expression fof 60 J T, Barrett J C. KAil, a metastasis suppressor gene for
the KAll protein in benign prostatic hyperplasia and prosprostate cancer on human chromosome llpll.2 [see
tate cancer. American Journal of Pathology 149(5):
comments]. Science, 268(5212):884-6, 1995). ~ 1 c and p27
1435-40, 1996): E-cadherin (Umbas R, Isaacs W B Brin(kipl) are involved in signaling pathway that inhibits cell
guier P P, Schaafsma H E, Karthaus H F, Oosterhof G 0,
proliferation (Fornaro M, Tallini G, Zheng D Q, Flanagan W
Debruyne FM, Schalken J A, Decreased E-Cadherin expres- 65 M, Manzotti M, Languino LR, p27(kipl) acts as a downsion is associated with poor prognosis is patients with
stream effector of and is coexpressed with the betalC
prostate cancer. Cancer Research, 52(18):5104-9, 1992,
integrin in prostatic adenocarcinoma. Journal of Clinical
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Investigation, 103(3):321-9, 1999). E-cadherin expression
Breast cancer is the most diagnosed cancer in women and
is progressively lost during the transformation of rat prostate
the second leading cancer related cause of death in women
cancer from non-invasive to invasive (Bussemakers M J,
(Greenlee R T, Murray T, Bolden S, Wingo PA, Cancer
van Moorselaar R J, Giroldi LA, Ichikawa T, Isaacs J T,
statistics, 1999, Ca: a Cancer Journal for Clinicians
Takeichi M, Debruyne F M, Schalken J A Decreased 5 2000;50:7-33). Breast ductal carcinoma in situ (hereinafter
expression of E-cadherin in the progression of rat prostatic
indicated as DCIS) incidence has increased dramatically
cancer. Cancer Research, 52(10):2916-22, 1992), and it has
since 1983 as a result of implementing screening programs
also been shown to be an invasion suppressor (Lou W, Krill
(Ernster V L, Barclay J. Increases in ductal carcinoma in situ
D, Dhir R, Becich M J, Dong J T, Frierson HF Jr. Isaacs W
(DCIS) of the breast in relation to mammography: a
B, Isaacs J T, Gao AC. Methylation of the CD44 metastasis 10 dilemma. [Review] [34 refs] Journal of the National Cancer
suppressor gene in human prostate cancer. Cancer Research,
Institute. Monographs, (22):151-6, 1997). DCIS is
59(10):2329-31, 1999). CD44 loss of expression is associdescribed as a malignant growth of epithelial cells within the
ated with high metastatic ability and transfection of CD44
ducts and lobules of the breast, and is believed to be the
suppresses metastasis without affecting tumorigenecity of
precursor of all invasive breast carcinoma. DCIS itself is
rat prostate cancer cells (Gao AC, Lou W, Dong J T, Isaacs 15 non-life-threatening; however, current treatment options for
J T. CD44 is a metastasis suppressor gene for prostatic
DCIS include masectomy, lumpectomy, radiotherapy or
cancer located on human chromosome llp13. Cancer
tamoxifen (Ernster V L, Barclay J. Increases in ductal
Research, 57(5):846-9, 1997). CD44 down-regulation is a
carcinoma in situ (DCIS) of the breast in relation to mamprognostic marker for prostate cancer (Noordzij M A, van
mography: a dilemma. [Review] [34 refs] Journal of the
Steenbrugge G J, Verkaik NS, Schroder F H, van der Kvast 20 National Cancer Institute. Monographs, (22):151-6, 1997;
T H. The prognostic value of CD44 isoforms in prostate
Hwang ES, Esserman LJ. Management of ductal carcinoma
cancer patients treated by radical prostatectomy. Clinical
in situ, [Review] [91 refs] Surgical Clinics of North
Cancer Research, 3(5):805-15, 1997).
America. 79(5):1007-30, viii, 1999). These treatment
Human prostate cancer histology is heterogeneous, or
options for DCIS are at best controversial due primarily to
"multi-focal" in nature (Isaacs J T, Bova G S, Prostate 25 a lack of precision in diagnosis and prognosis of whether the
Cancer. In The Genetic Basis of Human Cancer (Eds.
detected DCIS will progress to invasive breast cancer and
Vogelstein B and Kinzler K W), pp653-60, McGraw-Hill
whether recurrence is likely after treatment, usually with a
Health Professions Division, 1998 and Bova, 1998), with an
high percentage being invasive breast cancer (Zaugg K,
average of five lesions in a patient (Bastacky S I, Wojno K
Bodis S. Is there a role for molecular prognostic factors in
J, Walsh P C, Carmichael M J, Epstein J I. Pathological 30 the clinical management of ductal carcinoma in situ (DCIS)
features of hereditary prostate cancer. Journal of Urology,
of the breast [Review] [ 49 refs] Radiotherapy & Oncology,
153(3 Pt 2):987-92, 1995). Between the tumor regions of a
55(2):95-9, 2000). At present, histological grading (nuclear
prostate and within a single tumor region, the genetic causes
grading and whether come do-type necrosis is present) and
to the cancer are heterogeneous and independent as well
the size of the DCIS are used to provide assessments of risk
(Sakr WA, Macoska J A, Benson P, Grignon D J, Wolman 35 of DCIS to progress into invasive breast cancer (Zaugg K,
S R, Pontes J E, Crissman J D. Allelic loss in locally
Bodis S. Is there a role for molecular prognostic factors in
metastatic, multisampled prostate cancer. Cancer Research,
the clinical management of ductal carcinoma in situ (DCIS)
54(12):3273-7, 1994; Qian J, Bostwick D G, Takahashi S,
of the breast?. [Review] [ 49 refs] Radiotherapy & Oncology,
Borell T J, Herath J F, Lieber M M, Jenkins R B. Chromo55(2):95-9, 2000; Shaker B S, Sloane J P, DCIS grading
somal anomalies in prostatic intraepithelial neoplasia and 40 schemes and clinical implications. [Review] [ 40 refs]
carcinoma detected by fluorescence in situ hybridization.
Histopathology, 35(5):393-400, 19; van de Vijver M J.
Cancer Research, 55(22):5408-14, 1995; Mirchandani D,
Ductal carcinoma in situ of the breast: histological classifiZheng J, Miller G J, Ghosh AK, Shibata D K, Cote R J,
cation and genetic alterations. [Review] [ 69 refs] Recent
Roy-Burman P. Heterogeneity in intra tumor distribution of
Results in Cancer Research, 152:123-34, 1998). These
p53 mutations in human prostate cancer. American Journal 45 parameters are far from being adequate for making the most
of Pathology, 147(1):92-101, 1995). In the end, the best
accurate choice of treatment, resulting in a choice either
predictor of prostate cancer's potential to gain invasiveness
overly excessive or conservative, in either case, the patient
may be a consideration of a number of genes whose expreswill suffer unnecessarily. Molecular markers can help
sion levels change along the course of cancer development,
improve our ability to better diagnose DCIS and stratify
as demonstrated in principle by Greene et al. (Greene G F, 50 treatment options, especially the molecular markers that,
Kitadai Y, Pettaway CA, von Eschenbach AC, Buucana C
themselves, play a role in the progression of DCIS to
D, Fidler I J. Correlation of metastasis-related gene expresinvasive breast cancer (Zaugg K, Bodis S. Is there a role for
sion with metastatic potential in human prostate carcinoma
molecular prognostic factors in the clinical management of
cells implanted in nude mice using an in situ messenger
ductal carcinoma in situ (DCIS) of the breast?. [Review] [ 49
RNA hybridization technique. American Journal of 55 refs] Radiotherapy & Oncology, 55(2):95-9, 2000; SilverPathology, 150(5):1571-82, 1997). Hence, expanding the
stein M J, Masetti R. Hypothesis and practice; are there
repertory of such genes, including both the onco-genes and
several types of treatment for ductal carcinoma in situ of the
the suppressor genes, will enhance the accuracy and dependbreast?. [Review] [53 refs] Recent Results in Cancer
ability of this approach.
Research, 152:105-22, 1998). The tumorigenesis process is
As for the treatment options of prostate cancer, patients 60 a multi-step transformation in which molecular events escawith truly organ-confined prostate cancer can be cured by
late to the final stage of invasive phenotype (Silverstein M
radical prostatectomy. Patients with non-organ-confined
J, Masetti R. Hypothesis and practice: are there several types
prostate cancers, however, have very low survival rates and
of treatment for ductal carcinoma in situ of the breast?.
the current treatments are largely ineffective (Yagoda A,
[Review] [53 refs] Recent Results in Cancer Research,
Petrylak D, Cytotoxic chemotherapy for advanced hormone- 65 152:105-22, 1998). The conventional paradigm of protease
resistant prostate cancer. [Review] [ 63 refs] Cancer, 71(3
involvement in the development and progression of cancer
Suppl):1098-109, 1993).
has been the assignment of a usually negative role to the
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proteases, such as promoting tumor invasion (Mignatti P,
prostate gland by in situ hybridization histochemistry using
an antibody or an anti-sense RNA probe (Yu J X, Chao L,
Rifkin D B, Biology and biochemistry of proteinases in
Chao J. Prostasin is a novel human serine proteinase from
tumor invasion. [Review] [306 refs] Physiological Reviews,
seminal fluid. Purification, tissue distribution, and localiza73(1):161-95, 1993). In turn, the conventional paradigm of
protease inhibitors in relation to cancer is usually regard of 5 tion in prostate gland. Journal of Biological Chemistry,
269(29):18843-8, 1994; (Yu J X, Chao L, Chao J. Molecular
a beneficial effect for the presence of these molecules
cloning, tissue-specific expression, and cellular localization
(Kennedy A R. Chemopreventive agents: protease inhibiof human prostasin mRNA. Journal of Biological Chemistry,
tors. Pharmacol Therapeut 78:167-209, 1998). Recently,
270(22):13483-9, 1995). Molecular cloning of a full-length
however, the picture of a new paradigm is beginning to
human prostasin cDNA revealed that its predicted amino
emerge for several serine proteases in breast, prostate, and 10
acid residue sequence contains a carboxyl-terminal hydrotesticular cancers. A "normal epithelial cell specific-1" (NES
phobic region that can potentially anchor the protein on the
1) serine protease was found to be down-regulated in breast
membrane (Yu J X Chao L, Chao J. Molecular cloning,
and prostate cancers, and it functions as a tumor suppressor
tissue-specific expression, and cellular localization of
(Goyal J, Smith K M, Cowan J M, Wazer D E, Lee S W,
human prostasin mRNA. Journal of Biological Chemistry,
Band V. The role for NESl serine protease as a novel tumor 15 270(22):13483-9, 1995). At the amino acid level, prostasin
suppressor. Cancer Res 58:4782-4786, 1998). A prostateis similar to plasma kallikrein, coagulation factor XI, hepsin,
specific serine protease, prostase (Nelson P S, Gan L,
plasminogen, acrosin, prostase, and, in particular, testisin
Ferguson C, Moss P, Gelinas R, Hood L, Wang K. Molecular
(sharing 44% sequence identity) [Nelson P S, Gan L, Fercloning and characterization of prostase, an androgenuuson C, Moss P, Gelinas R, Hood L, Wang K. Molecular
regulated serine protease with prostate-restricted expression. 20 cloning and characterization of prostase, an androgenregulated serine protease with prostate-restricted expression,
Proceedings of the National Academy of Sciences of the
Proceedings of the National Academy of Sciences of the
United States of America, 96(6):3114-9, 1999), was shown
United States of America, 96(6):3114-9, 1999; Hooper JD,
to be expressed in normal prostate but not in prostate cancer
Nicol D L, Dickinson J L, Eyre HJ, Scarman AL, Normy le
cell lines DU-145 and PC-3. The expression of a testisspecific serine protease, testisin, was shown to be lost in 25 J F, Stuttgen MA, Douglas M L, Loveland KA, Sutherland
G R, Antalis T M. Testisin, a new human serine proteinase
testicular cancer through either a loss of gene (Hooper J D,
expressed by premeiotic testicular germ cells and lost in
Nicol D L, Dickinson J L, Eyre HJ, ScarmanAL, Normyle
testicular germ cell tumors. Cancer Research, 59(13):
J F, Stuttgen MA, Douglas M L, Loveland KA, Sutherland
3199-205, 1999; Yu J X, Chao L, Chao J. Molecular
G R, Antalis T I. Testisin, a new human serine proteinase
cloning, tissue-specific expression, and cellular localization
expressed by premeiotic testicular germ cells and lost in 30
of human prostasin mRNA. Journal of Biological Chemistry,
testicular germ cell tumors. Cancer Research, 59(13):
270(22): 13483-9, 1995). A membrane-bound Xenopus kid3199-205, 1999) or methylation in the promoter (Boucaut
ney epithelial cell sodium channel-activating protease
K, Douglas M, Clements J, Antalis T. The serine proteinase
(CAPl) was shown to be highly homologous to human
testisin may act as a tumor and/or growth suppressor in the
prostasin as well (sharing 53% sequence identity at the
testis and may be regulated by DNA methylation. Cancer 35 amino acid level) (Vallet V, Chraibi A, Gaeggeler H P,
Genetics and Tumor Suppressor Genes, Cold Spring Harbor
Horisberger J D, Rossier B C. An epithelial serine protease
Laboratory, 2000). Further, transfection of human testicular
activates the amiloride-sensitive sodium channel. Nature,
cancer cells with a testisin cDNA reduced the tumor growth
389(6651):607-10, 1997). Prostasin is encoded by a singleof xenografts of these cells in nude mice, suggesting a tumor
copied gene, which is located on human chromosome
suppressor function for testisin (Boucaut K, Douglas M, 40 16pll.2 (Yu J X, Chao L, Ward DC, Chao J. Structure and
Clements J, Antalis T. The serine proteinase testisin may act
chromosomal localization of the human prostasin (PRSS8)
as a tumor and/or growth suppressor in the testis and may be
gene. Genomics, 32(3):334-40, 1996). The secreted prostaregulated by DNAmethylation. Cancer Genetics and Tumor
sin cleaves synthetic substrates in vitro preferentially at the
Suppressor Genes, Cold Spring Harbor Laboratory, 2000).
carboxyl-terminal side ofArg residue, and is thus considered
The testisin serine protease is potentially membrane-bound 45 a trypsin-like serine protease (Yu J X, Chao L, Chao J.
Prostasin is a novel human serine proteinase from seminal
as suggested by its structure and confirmed by immunohisfluid. Purification, tissue distribution, and localization in
tochemistry gene (Hooper J D, Nicol D L, Dickinson J L,
prostate gland. Journal of Biological Chemistry, 269(29):
Eyre HJ, ScarmanAL, Normyle J F, Stuttgen MA, Douglas
M L, Loveland KA, Sutherland G R, Antalis T M. Testisin,
18843-8, 1994). The physiological function of prostasin,
a new human serine proteinase expressed by premeiotic 50 however, has remained unknown. By comparing gene
testicular germ cells and lost in testicular germ cell rumors.
expression of normal tissues, pre-invasive cancer, and invaCancer Research, 59(13):3199-205, 1999.) Prostasin serine
sive cancer, it would be highly advantageous to discover
protease is an acidic protein (pl 4.5-4.8) of approximately
molecular markers that display a differential expression
pattern between the pre-invasive and the invasive pheno40 kDa in molecular mass (Yu J X, Chao L, Chao J,
Prostasin is a novel human serine proteinase from seminal 55 types and use these markers for a more precise diagnosis and
prognosis of prostate and/or breast cancers. With the
fluid. Purification, tissue distribution, and localization in
prostate gland. Journal of Biological Chemistry. 269(29):
enhanced precision in diagnosis and prognosis, treatment
18843-8, 1994), it is predominantly made in the prostate
options for patients with DCIS could then be stratified.
gland (-140 ng/mg protein), with lesser amounts (2-6 ng/mg
Those with low risks of developing invasive breast cancer
protein) also found in the bronchi, colon, kidney, liver, lung, 60 will have a higher confidence in choosing breast-conserving
options, while those at high risks will ponder more aggrespancreas, and the salivary glands (Yu J X, Chao L, Chao J.
sive options with the necessary follow-up treatments.
Prostasin is a novel human serine proteinase from seminal
Similarly, those males with low risks of developing invasive
fluid. Purification, tissue distribution, and localization in
prostate gland. Journal of Biological Chemistry, 269(29):
prostate cancer will have a higher confidence in choosing
18843-8, 1994). Prostasin is secreted in the prostatic fluid, 65 prostate-conserving options, while those at high risks will
ponder more aggressive options with the necessary followand can be detected in the semen (-9 µg/ml). Prostasin
up treatments.
expression is localized to the epithelial cells of human
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SUMMARY OF THE INVENTION
BRIEF DESCRIPTION OF THE FIGURE
The first objective of the present invention is to reduce
FIG. 1 is a diagrammatic representation of the analysis of
deficiencies in the prior art with specific regard to differenprostasin indicative of the absence or existence, or of the
tial diagnosis of invasive prostate and breast cancers and to
invasiveness of human prostate carcinoma.
treatment of invasive and metastatic prostate and breast 5
FIG. 2 is a diagrammatic representation of the analysis of
cancers.
prostasin indicative of the absence or existence, or of the
The second objective of the present invention is to proinvasiveness of human mammary carcinoma.
vide a new marker for prostate and breast cancer.
FIG. 3 shows human prostasin expression in prostate
The third objective of the invention is to provide as a drug
to patients with carcinoma of the prostate via delivery of a 10 epithelial cells.
FIG. 4A shows immunohistochemical detection of prosfunctional prostasin gene.
tasin protein in benign human prostate tissues.
The fourth objective of the invention is to provide as a
drug to patents with carcinoma of the prostate via delivery
FIG. 4B is an enlarged view of the boxed region of FIG.
of a functional prostasin cDNA.
4A.
The fifth objective of the invention is to provide as a drug 15
FIG. 4C shows immunohistochemistry of benign human
to patents with carcinoma of the breast via delivery of a
prostate tissues with prostasin antibody omitted in the
functional prostasin gene.
procedures, no epithelial cells displayed any staining.
The sixth objective of the invention is to provide as a drug
FIG. 4D is an enlarged view of the boxed region of FIG.
to patents with carcinoma of the breast via delivery of a
20 4C.
functional prostasin cDNA.
FIG. 4E shows immunohistochemistry of human prostate
This invention identifies prostasin serine protease as a
tumor with prostasin antibody omitted in the procedures, no
potential marker, and as a tumor invasion suppressor for
epithelial cells displayed any staining.
prostate and breast cancers and thus provides methods (a),
FIG. 4F shows immunohistochemical detection of pros(b), and (c) of determining invasiveness levels of human 25
tasin protein in benign human prostate tissue surrounded by
carcmomas:
prostate carcinomas.
(a) using prostasin protein levels, comprising the steps of:
FIG. 4G shows immunohistochemical detection of prossampling a human carcinoma tissue; determining prostasin protein in Gleason grade 2 prostate tumor.
tasin protein levels in the human carcinoma tissue;
FIG. 4H is an enlarged view of the boxed region of FIG.
preferably by applying an immunological reagent- 30
4G.
antibody to said tissue wherein the reagent-antibody
FIG. 4I shows immunohistochemical detection of prostabecomes bound to prostasin protein in said tissue, and
determining invasiveness of the human carcinoma tissin protein in Gleason grade 3 prostate tumor.
sue based on the prostasin protein levels; or
FIG. 41 is an enlarged view of the boxed region of FIG.
(b) using prostasin mRNA levels, comprising the steps of: 35 41.
sampling a human carcinoma tissue; determining prosFIG. 4K shows immunohistochemical detection of prostasin mRNA levels in the human carcinoma tissue
tasin protein in Gleason grade 4 prostate tumor.
preferably by applying prostasin-specific anti-sense
FIG. 4L is an enlarged view of the boxed region of FIG.
RNA probes in an in situ hybridization to determine the
4K.
prostasin mRNA levels in the separated human carci- 40
FIG. 5 shows human prostasin expression in human breast
noma tissue the determination of the prostasin mRNA
cancer cell lines.
levels in the separated human carcinoma sample tissue;
FIG. 6 shows promoter hypermethylation of the human
to make possible and determining invasiveness of the
prostasin
gene in human prostate and breast cancer cell lines.
human carcinoma tissue based on the prostasin mRNA
FIG.
7
shows prostasin protein expression and in vitro
levels; or
45
invasive properties of the DU-145 and the PC-3 transfec(c) (c) using prostasin gene promoter DA methylation
tants.
levels, comprising the steps of: sampling a human
FIG. 8 shows prostasin protein expression and in vitro
carcinoma tissue; determining prostasin gene promoter
invasive properties of the MDA-MB-231 and the MDADNA methylation levels in the human carcinoma
tissue, preferably by applying prostasin-promoter- 50 MB-435s transfectants.
specific oligonucleotide primers in a PCR to determine
DESCRIPTION OF THE PREFERRED
the prostasin gene promoter DNAmethylation levels in
EMBODIMENT
the sampled human carcinoma tissue and determining
Before explaining the disclosed embodiment of the
invasiveness of the human carcinoma tissue based on
the prostasin gene promoter DNA methylation levels, 55 present invention in detail it is to be understood that the
invention is not limited in its application to the details of the
as well as a method of treating invasive human carciparticular arrangement shown since the invention is capable
nomas comprising the steps of: incorporating human
of other embodiments. Also, the terminology used herein is
prostasin nucleic acid into a selected gene delivery
for the purpose of description and not of limitation.
vector nucleic acid to form a recombinant nucleic acid;
Using RT-PCR and western blot analyses, prostasin propreferably wherein the nucleic acid includes a gene or 60
cDNA delivering the recombinant nucleic acid into a
tein and mRNA expression were found in normal human
human carcinoma; and reducing invasiveness of the
prostate epithelial cells and the human prostate cancer cell
human carcinoma.
line LNCaP, but discovered not present in the highly invasive human prostate cancer cell lines DU-145 and PC-3.
Further objects and advantages of this invention sill be
apparent from the following detailed description of a pres- 65 Immunohistochemistry studies of human prostate cancer
ently preferred embodiment, which is illustrated schematispecimens revealed a down-regulation of prostasin in highcally in the accompanying drawings.
grade tumors.
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Using RT-PCR and western blot analyses, prostasin proRefer now to FIG. 3 which shows human prostasin
tein and mRNA expression were found in a non-invasive
expression in prostate epithelial cells. By means of western
human breast cancer cell line, MCF-7, while invasive human
blot analysis (upper panel), prostasin (as a 40-kDa band) was
breast cancer cell lines MDA-MB-231 and MDA-MB-435s
detected in normal human prostate epithelial cells (CCwere also discovered not to express either the prostasin 5 2555) and the LNCaP cells, but not in the DU-145 or PC-3
protein or the mRNA. A non-invasive human breast cancer
cells. An equal amount of total protein (100 µg) was loaded
cell line, MDA-MB-453, was shown to express prostasin
for each sample. At the mRNA level, human prostasin
mRNA but not prostasin protein. Examination of the prosmRNA (via a 232-bp amplified DNA band) was detected in
tasin gene promoter in the human prostate and breast cancer
normal prostate epithelial cells (CC-2555) and the LNCaP
cell lines by Southern blot analysis revealed heterogeneous
10 cells, but not in the DU145 or PC-3 cells as analyzed by
methylation of the promoter in DU-145, PC-3 and MDART-PCR/Southern blot hybridization (middle panel).
MB-453 cells, and homogeneous methylation of the proCo-amplification of a 556-bp human ~-actin message (as
moter in MDA-MB-231 and MDA-MB-435s cells. The
shown in the gel photograph in the lower panel) confirmed
prostasin gene promoter in normal human prostate epithelial
the quality and the quantity of the RNA applied in each
cells, the LNCaP and the prostasin gene promoter in the
RT-PCR.
human prostate and breast cancer cell lines by Southern blot 15
Expression of prostasin protein is reduced in high-grade
analysis revealed heterogeneous methylation of the prohuman prostate tumor. Prostatectomy specimens from 39
moter in DU-145, PC-3 and MDA-MB-453 cells, and homopatients (128 sections) were subjected to immunohistochemgeneous methylation of the promoter in MDA-MB-231 and
istry using a prostasin-specific antibody. Overall, in nonMDA-MB-435s cells. The prostasin gene promoter in normal human prostate epithelial cells, the LNCaP and the 20 tumor or benign prostate epithelia, 89.0% of the examined
areas demonstrated positive staining for prostasin protein
MCF-7 cells was shown to be unmethylated. Transfection of
and 11.0% were considered negative (based on the scoring
DU-145 and PC-3 cells with a full-length human prostasin
system used for HercepTest™, DAKO Corporation,
cDNArestored prostasin expression and reduced the in vitro
invasiveness by 68% and 42%, respectively. Transfection of
Carpinteria, Calif.). In all tumor specimens that were
MDA-MB-231 and MDA-MB-435s cells with a full-length 25 examined, prostasin was detected in 93.3% of the low
human prostasin cDNA restored prostasin expression and
Gleason grade areas (~grade 2), 44.4% of Gleason grade 3
reduced the in vitro invasiveness by 50% for either cell line.
areas, 21.1 % of Gleason grade 4 areas, but not in Gleason
Cell proliferation was unaffected by re-expression of prosgrade 5 areas (data summarized in Table 1). The mean
tasin. Our data indicate that prostasin is implicated in normal
prostasin immunostaining score was found significantly
prostate biology and its down-regulation in prostate cancer, 30 decreased in high-grade prostate tumors as compared to
and its absence in invasive prostate and breast cancer cell
non-tumor areas (ANOVA, p<0.0001).
lines indicates increased invasiveness. Our results also indiRepresentative staining images of non-tumor (benign)
cate that delivering a functional human prostasin gene to
areas and prostate tumor areas are shown in FIGS. 4a-4l,
invasive prostate and breast cancers can reduce the invawhich provides immunohistochemical detection of prostasin
siveness.
35 protein in tissues. Paraffin-embedded human prostate secFor a facile understanding of the invention embodied
tions were stained for prostasin protein expression evaluaherein, reference should now be made to FIGS. 1and2. FIG.
tion using a specific antibody as described (Yu J X, Chao L,
1 sets forth a schematic for determining if a male has
Chao J. Prostasin is a novel human serine proteinase from
prostate cancer. Human blood 10 is taken from the male and
seminal fluid. Purification, tissue distribution, and localizaanalyzed for the presence of prostasin serine protease 14. If 40 tion in prostate gland. Journal of Biological Chemistry,
NO 12 prostasin is found, there is probably little or no
269(29):18843-8, 1994). Prostasin positive staining (brown
cancer. If there is a presence YES 16 of prostasin serine
color) was detected in the cytoplasm and apical membrane
protease 14, there is prostate cancer.
in non-tumor or benign epithelial cells.
If a biopsy of the prostate gland 20 is analyzed for the
The prostasin protein was detected in the cytoplasm and
presence of a normal amount YES 22 of prostasin serine 45 on the plasma membrane (apical) of benign epithelial cells
protease 14, there is no cancer or there is non-invasive
lining the secretory lumen as well as in the secretion inside
cancer. If there is NO 24 or Reduced 26 amount of prostasin
the lumen (FIGS. 4A and 4B, score 3, or+++), confirming
serine protease 14, there is invasive cancer.
the results of (Yu J X, Chao L, Chao J. Prostasin is a novel
FIG. 2 sets forth a schematic for determining if a female
human serine proteinase from seminal fluid. Purification,
has breast cancer. Human blood 100 is taken from the female 50 tissue distribution, and localization in prostate gland. Journal
and analyzed for the presence of prostasin serine protease
of Biological Chemistry, 269(29):18843-8, 1994). When a
140. If NO 120 prostasin is found, there is prospectively no
pre-immune rabbit serum was used in place of the prostasin
cancer. If there is a presence YES 160 of prostasin serine
antiserum, no stamina was observed in either the non-tumor
protease 140, there is breast cancer. If a biopsy of the breast
epithelia (FIGS. 4C and 4D) or tumor epithelia (FIG. 4E).
200 is analyzed for the presence of YES 220 of prostasin 55 Tumor epithelia displayed various degree: of prostasin
serine protease 140, there is no invasive cancer but may be
immunostaining as shown in FIGS. 4F-4L. In Gleason grade
non-invasive cancer. If there is NO 240 or Reduced 260
1-2 tumors, moderate prostasin staining is seen in the
amount of prostasin serine protease 140, there is invasive
cytoplasm and on the plasma membrane of some epithelial
cancer.
cells, as well as in the secretion in the lumen (FIGS. 4G and
The levels of prostasin protein in the epithelial cells of the 60 4H, score 2, or ++ ). In Gleason grade 3 tumors, a lesser
human prostate gland can be used as a diagnostic marker for
number of epithelial cells displayed the moderate level
prostasin staining (FIGS. 4I and 41). In Gleason grade 4
the potential invasiveness of prostate tumors. The supporting evidence came from our findings that two invasive
tumors, most epithelial cells did not show any prostasin
human prostate cancer cell lines DU-145 and PC-3 do not
staining, while some prostasin staining can be seen in rare,
express prostasin while normal prostate epithelial cells and 65 sporadic tumor cells (FIGS. 4K and 4L, as indicated by the
a non-invasive prostate cancer cell line LNCaP express both
arrow, score 0). Genetically, prostate tumors are heterogeneous and multi-focal in nature, in that one patient's grossthe prostasin mRNA and protein
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anatomy tumor comes from multiple initial lesions which
prostasin promoter in these cells. For DU-145, PC-3, and
MDA-MB-453 DNA, both the 1,052-bp and the 1,275-bp
are caused by different initial transformation events and
progress to different stages by different ensuing transformafragments are generated in the methylation-sensitive
tions (Isaacs J T, Bova GS. Prostate Cancer. In The Genetic
digestion, suggesting incomplete methylation (one of two or
Basis of Human Cancer (Eds. Vogelstein B and Kinzler K 5 more chromosomes) or clonal methylation in a subpopulation of cells. For the MDA-MB-231 and MDA-MBW), pp653-60, McGraw-Hill Health Professions Division,
1998). The Gleason grading, when used as a percentage of
435, however, the Hpa II digestion did not yield the 1.052-bp
but rather gave the 1,275-bp fragment. This homogeneous
each cancer occupied by Gleason grade 4/5 areas, is indemethylation pattern indicates that the Msp I/Hpa II site, at
pendently associated with prostate cancer progression
(Stamey T A, McNeal J E, Yemoto C M, Sigal B M, 10 location-95 (relative to the transcription initiation site) of the
prostasin promoter, is methylated (hypermethylated) in
Johnstone I M. Biological determinants of cancer progresthese DNA samples. Signal intensity variation may be
sion in men with prostate cancer. JAMA 281:1395-1400,
attributed to aneuploidy.
1999). We found a significant decrease of prostasin expresAn examination of the prostasin gene promoter region for
sion in the high-grade, i.e., the more progressively transDNA methylation differences among human prostate and
formed tumors.
15 breast cancer cell lines has been made,(see FIG. 6). We
As earlier indicated, FIG. 5 shows human prostasin
found that cells that express prostasin, normal prostate
expression in human breast cancer cell lines. By means of
epithelial, LNCaP, and MCF7, are unmethylated in the
western blot analysis (upper panel), prostasin (as a 40-kDa
prostasin promoter while MDA-MB-453 showed heterogeband) was detected in MCF-7 cells, but not in MDA-MBneous prostasin promoter methylation. For cells that do not
453, MDA-MB-231, or MDA-MB-435s cells. An equal 20 express prostasin, DU-145 and PC-3 showed heterogeneous
amount of total protein (100 µg) was loaded for each sample.
prostasin promoter methylation while MDA-MB-231 and
At the mRNA level, human prostasin mRNA (via a 232-bp
MDA-MB-435 showed homogeneous hypermethylation in
amplified DNA band) was detected in MCF-7 and MDAthe promoter region of the prostasin gene.
MB-453 cells, but not in the MDA-MB-231 or MDA-MBTwo human prostate cancer cell lines that do not express
435s cells as analyzed by RT-PCR/Southern blot hybridiza- 25 prostasin, the highly invasive DU-145 and PC-3, show
tion (lower panel).
heterogeneous methylation in the promoter region of the
prostasin gene. The result suggests that at least one of the
Prostasin mRNAexpression is seen absent in two invasive
two (or more) chromosome 16's of these cell lines is
human breast cancer cell lines while two non-invasive breast
methylated at the prostasin gene locus. The prostasin gene
cancer cell lines express prostasin mRNA or protein. Analysis of prostasin expression in human breast cancer cell lines 30 on the unmethylated chromosome may contain mutations
that silenced the expression. An alternative explanation for
showed that the non-invasive MCF-7 and MDA-MB-453
the heterogeneous methylation pattern is that the methylacells express the prostasin mRNA while the highly invasive
tion occurs in clonal cell populations, however, the lack of
MDA-MB-231 and MDA-MB-435s cells do not express the
detectable prostasin mRNA in our RT-PCR-Southern blot
prostasin mRNA (see FIG. 5). Expression of prostasin
mRNA in normal human breast can be demonstrated by the 35 analysis in the DU-145 and PC-3 cells argues against this
possibility.
presence of two GenBank™ normal human breast EST
The significance of the finding on prostasin gene promoter
sequences coding for prostasin (Accession numbers
hypermethylation in prostate or breast cancer is that the
R48653, and R48557). The MCF-7 cells also express the
measurement of prostasin down-regulation as a cancer
prostasin protein as determined by western blot analysis
(again see FIG. 5).
40 marker may be achieved by using a binary assay (yes-or-no),
instead of a gradually decreasing quantity in the immunoProstasin down-regulation in prostate or breast cancer can
histochemistry assay (which is quite arbitrary).
be caused by promoter methylation or gene-specific mutaRe-expression of human prostasin protein in invasive
tion. Prostasin expression decreases with increasing prostate
human prostate and breast cancer cells reduces invasiveness
cancer grade and is absent in invasive prostate and breast
cancer cell lines. The chromosomal locus where the human 45 in vitro. At this point, reference should be made to FIG. 7
which shows the prostasin protein expression and in vitro
prostasin gene is, 16pll.2, however, is not known to be an
invasive properties of the DU-145 and the PC-3 transfecLOH hot-spot in prostate cancer or in breast cancer. Epigetants. DU-145 or PC-3 cells transfected with either a vector
netic events (such as DNA methylation) may be an alternaDNA (labeled as "vector") or a prostasin cDNA construct
tive mechanism of loss of expression for tumor suppressors
or invasion suppressors. Refer now to FIG. 6 which shows 50 (labeled as "prostasin") were analyzed by a western blot
analysis using a prostasin-specific antibody (upper panel) or
promoter hypermethylation of the human prostasin gene in
subjected to an in vitro Matrigel chemoinvasion assay
human prostate and breast cancer cell lines. Genomic DNA
(lower panel) as described in (Liu D F, Rabbani S A
( 5 µg) from the various cell lines (as indicated in the figure)
Induction of urinary plasmiinogen activator by retinoic acid
were digested with the following restriction enzyme combinations. Xho l/BamH I (X/B, flanking cuts of the 55 results in increased invasiveness of human prostate cancer
cells PC-3. Prostate, 21(5):269-76, 1995). The expressed
methylation-sensitive site), Xho I/BamH I/Msp I (X/B/M),
human prostasin protein (a 40-kDa band) was detected in the
or Xho l/BamH l/Hpa II (X/B/H). The digests were resolved
prostasin cDNA-transfected DU-145 or PC-3 cells, but not
in a 0.8% agarose gel and transferred to an Immobilon-N
in the vector-transfected cells. In the Matrigel chemoinvamembrane for hybridization with a nick-translated prostasin
promoter probe (bases 703-1469 of the prostasin gene 60 sion assay, the vector-transfected cells are expressed as
being 100% invasive (solid bar), the open bar represents the
sequence U33446). The probe detects a promoter fragment
relative invasiveness of the human prostasin cDNAof 1,275 bp, which is cut by the methylation-insensitive
transfected cells. The data were analyzed by a Student t-test
enzyme Msp I to yield a 1,052-bp fragment for all DNA
using the StatView software (Abacus Concepts, Inc.,
samples. The methylation-sensitive isoschizomer Hpa II
yields the 1,052-bp fragment in the CC-2555 (normal pros- 65 Berkeley, Calif.).
It can be seen that Polyclonal DU-145 and PC-3 cells
tate epithelial cells), the LNCaP, and the MCF-7 samples,
transfected with the human prostasin cDNA (designated
indicating the hypomethylated or unmethylated state of the
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intrinsic limitation that the "positive" identifications are not
DU-145/Pro, and PC-3/Pro, respectively) were confirmed to
express the human prostasin protein, as shown in the western
always confirmed for the "diagnosed" disease. Biopsy is still
blot analysis of the cell lysate (FIG. 7, upper panel). The
required for a true positive identification of prostate cancer
vector-transfected cells, designated DU-145/Vector or PC-3/
even in the case of the application of the PSA prostate cancer
Vector, respectively, were used as negative control in the 5 marker (Catalana W J, Partin AW, Slawin KM, Brawer M
western blot. A further examination of the DU-145/Pro and
K, Flanigan R C, Patel A, Richie J P, deKernion J B, Walsh
the PC-3/Pro cells by immunocytochemistry confirmed that
P C, Scardino P T, Lange P H, Subong E N, Parson R E,
100% of the cells expressed the prostasin protein (data not
Gasior G H, Loveland K G, Southwick P C. Use of the
shown). In in vitro Matrigel chemoinvasion assays (FIG. 7,
percentage of free prostate-specific antigen to enhance diflower panel), the invasiveness of DU-145/Pro cells was 10 ferentiation of prostate cancer from benign prostatic disease:
determined to be at 32% of that ofDU-145. Vector cells (or,
a prospective multicenter clinical trial [see comments].
the reduction of invasiveness was at 68%). The invasiveness
JAMA, 279(19):1542-7, 1998). As stated above, it has been
of PC-3/Pro cells was determined to be at 58% of that of
demonstrated in principle that many markers used in a
PC-3Nector cells (or, the reduction of invasiveness was at
multivariate approach may provide a highly accurate diag42%). We performed in vitro cell proliferation assays on 15 nosis (Greene G F, Kitadai Y, Pettaway CA, von Eschenbach
DU-145/Pro vs. DU-145Nector cells, and on PC-3/Pro vs.
A C, Bucana C D, Fidler I J. Correlation of metastasisPC-3/Vector cells, but did not observe any difference
related gene expression with metastatic potential in human
between the growth rates of the prostasin cDNA-transfected
prostate carcinoma cells implanted in nude mice using an in
or the vector-transfected cells over an 8-day period (data not
situ messenger RNA hybridization technique. American
shown).
20 Journal of Pathology 150(5):1571-82, 1997). From the
Forced re-expression of human prostasin in two invasive
standpoint of prostate cancer genetics, the multivariate
human breast cancer cell lines reduced invasiveness. A
approach is well supported by our current understanding. A
full-length human prostasin cDNA under the control of an
serine protease structurally and genetically related to the
RSV promoter was transfected into the invasive breast
PSA, the hK2 (human glandular kallikrein 2) has shown
cancer MDA-MB-231 and MDA-MB-435 cells. Reference 25 some promise of joining the list of markers applicable for
should be made to FIG. 8 which shows prostasin protein
prostate cancer diagnosis (Saedi M S, Hill T M, Kuusexpression and in vitro invasive properties of the MDAReichel K, Kumar A, Payne J, Mikolajczyk SD, Wolfert R
MB-231 and the MDA-MB435s transfectants. MDA-MBL, Rittenhouse H G. The precursor form of the human
231 and MDA-MB-435s cells transfected with either a
kallikrein 2, a kallikrein homologous to prostate-specific
vector DNA (labeled as "vector") or a prostasin cDNA 30 antigen, is present in human sera and is increased in prostate
construct (labeled as "prostasin") were analyzed by a westcancer and benign prostatic hyperplasia. Clinical Chemistry,
ern blot analysis using a prostasin-specific antibody (upper
44(10):2115-9, 1998). Structurally and in prostate gland
panel) or subjected to an in vitro Matrigel chemoinvasion
biology, prostasin shares many common characteristics with
assay (lower panel) as referenced in (Liu D F, Rabbani S A
both PSA and hK2, as being a secreted serine protease made
Induction of urinary plasminogen activator by retinoic acid 35 in large abundance in prostate epithelial cells (Yu J X, Chao
results in increased invasiveness of human prostate cancer
L, Chao J. Prostasin is a novel human serine proteinase from
cells PC-3. Prostate, 27(5):269-76, 1995). The expressed
seminal fluid. Purification, tissue distribution, and localizahuman prostasin protein (a 40-kDa band) was detected in the
tion in prostate gland. Journal of Biological Chemistry,
prostasin cDNA-transfected MDA-MB-231 and MDA-MB269(29):18843-8, 1994; Yu J X, Chao L, Chao J. Molecular
435s cells, but not in the vector-transfected cells. In the 40 cloning, tissue-specific expression, and cellular localization
Matrigel chemoinvasion assay the vector-transfected cells
of human prostasin mRNA. Journal of Biological Chemistry,
are expressed as being 100% invasive (solid bar), the open
270(22):13483-9, 1995). While high-grade prostate cancer
bar represents the relative invasiveness of the human proscells produce less PSA protein than normal prostate cells or
tasin cDNA-transfected cells. The data were analyzed by a
low-grade prostate cancer cells (Hakalahti L, Vihko P,
Student t-test using the StatView software (Abacus 45 Henttu P, Autio-Harmainen H, Saini Y, Vihko R. Evaluation
Concepts, Inc., Berkeley, Calif.).
of PAP and PSAgene expression in prostatic hyperplasia and
Stable, polyclonal, episomal transfectants were obtained
prostatic carcinoma using northern-blot analyses, in situ
and the expression of human prostasin protein was conhybridization and immunohistochemical stainings with
firmed by western blot analysis (FIG. 8, upper panel). In in
monoclonal and bispecific antibodies. International Journal
vitro Matrigel chemoinvasion assays, the invasiveness of 50 of Cancer, 55(4):590--7, 1; Sakai H, Yogi Y, Minami Y,
either cell lines expressing human prostasin was reduced by
Yushita Y, Kanetake H, Saito Y. Prostate specific antigen and
50% as compared to the vector-transfected controls (FIG. 8,
prostatic acid phosphatase immunoreactivity as prognostic;
lower panel).
Sakai H, Yogi Y, Minami Y, Yushita Y, Kanetake H, Saito Y.
Taken together, the foregoing evidences linking prostasin
Prostate specific antigen and prostatic acid phosphatase
level reduction or protasin absence to the invasiveness of 55 immunoreactivity as prognostic), the serum PSA levels in
prostate and breast cancer cell lines, or linking prostasin
prostate cancer patients increase due to tissue damage
expression to reduced invasiveness. The evidence qualifies
caused by invasive cancer (Rittenhouse H G, Finlay J A,
prostasin as an invasion suppressor, which thus is a marker
Mikolajczyk SD, Partin AW. Human Kallikrein 2 (hK2) and
for diagnosis of invasiveness of prostate and breast cancers,
prostate-specific antigen (PSA): two closely related, but
or as a therapeutic agent to treat invasive prostate and breast 60 distinct, kallikreins in the prostate. [Review] [ 457 refs]
cancers.
Critical Reviews in Clinical Laboratory Sciences, 35(4):
275-368, 1998). By comparison, we also believe prostasin
Pathological grading by the Gleason system is performed
is in the circulation of prostate cancer patients. As a result,
after either surgery or biopsy, both highly invasive
a blood test for the circulating prostasin to indicate the
procedures, while blood tests such as that for the PSA
prostate cancer marker can offer the hope of accurate diag- 65 presence and/or the stage of prostate cancer would be highly
nosis and prognosis without the harm of an invasive proceuseful. (as illustrated in FIG. 1). In principal, the feasibility
of a blood test based on prostasin detection to indicate
dure. In practice, however, single markers suffer from an
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cancer has been demonstrated by Berteau et al. (1999).
These authors (Berteau P, Laribi Eschwege P, Lebars I,
Dumas F, Benoit G, Lorie S. Prostasin mRNA to detect
prostate cells in blood of cancer patients. Clinical and
Chemical Laboratory Medicine 37 (SS): S119, 1999), demonstrated a highly promising potential of using prostasin as
a marker to detect circulating prostate epithelial cells, a sign
of prostate tissue damage caused by invasive prostate cancer
leading to the dissemination of prostate epithelial cells into
the circulation. It is expected that a blood test for circulating
prostasin to indicate the presence and/or the stage of breast
cancer would be highly useful. (as illustrated in FIG. 2).
In summary of the invention, it has been taught herein
that: protein prostasin as well as its MRA levels and its gene
promoter DNA methylation levels can be used to determine
the invasiveness level of human carcinomas; and, provide a
method of treating invasive human carcinomas by delivery
thereto of a recombinant nucleic acid formed by a human
prostasin nucleic acid incorporated into a selected gene
delivery vector. Those teachings are repeated for emphasis
in the following:
1. Immunohistochemistry studies of human prostate cancer specimens revealed a down-regulation of prostasin
in high-grade tumors.
2. Using RT-PCR and western blot analyses, prostasin
protein and mRNA expression were found in a noninvasive human breast cancer cell line MCF-7, while
invasive human breast cancer cell lines, MDA-MB-231
and MDA-MB-435s were found not to express either
the prostasin protein or the mRNA. A non-invasive
human breast cancer cell line, MDA-MB-453, was
shown to express prostasin mRNA but not prostasin
protein; and,
3. Examination of the prostasin gene promoter in the
human prostate and breast cancer cell lines by Southern
blot analysis revealed heterogeneous methylation of the
promoter in DU-145, PC-3 and MDA-MB-453 cells,
and homogeneous methylation of the promoter in
MDA-MB-231 and MDA-MB-435s cells. The prostasin gene promoter in normal human prostate epithelial
cells, the LNCaP and the MCF-7 cells was shown to be
unmethylated. Transfection of DU-145 and PC-3 cells
with a full-length human prostasin cDNA restored
prostasin expression and reduced the in vitro invasiveness by 68% and 42%, respectively. Transfection of
MDA-MB-231 and MDA-MB-435s cells with a fulllength human prostasin cDNA restored prostasin
expression and reduced the in vitro invasiveness by
50% for either cell line.
The preferred methods of separating sampled human
carcinoma tissue from neighboring normal tissues is by laser
capture micro-dissection.

While the invention has been described, disclosed, illustrated and shown in various terms of certain embodiments or
modifications which it has presumed in practice, the invention is not intended to be, nor should it be deemed to be,
limited thereby and such other modifications or embodiments as may be suggested by the teachings herein are
particularly reserved especially as they fall within the
breadth and scope of the claims here appended.
We claim:
1. A method of determining human prostate carcinomas
non-invasiveness using prostasin MRNAlevels, comprising
the steps of:
sampling a human prostate carcinoma tissue;
determining prostasin mRNA levels in the human carcinoma tissue; and
determining the human prostate carcinoma tissue is not
invasive based on the prostasin mRNA levels.
2. The method of determining human prostate carcinomas
non-invasiveness as in claim 1, wherein the step of determining prostasin mRNA levels includes the step of:
applying prostasin-specific oligonucleotide primers in an
RT-PCR to determine the prostasin mRNAlevels in the
sampled human prostate carcinoma tissue.
3. The method of determining human prostate carcinomas
non-invasiveness as in claim 1, wherein the step of determining prostasin mRNA levels includes:
applying prostasin-specific anti-sense RNA probes in an
in situ hybridization to determine the prostasin mRNA
levels in the sampled human carcinoma tissue.
4. A method of determining human breast carcinomas
non-invasiveness using prostasin MRNAlevels, comprising
the steps of:
sampling a human breast carcinoma tissue;
determining prostasin mRNA levels in the human breast
carcinoma tissue; and
determining the human breast carcinoma tissue is not
invasive based on the prostasin mRNA levels.
5. The method of determining human breast carcinomas
non-invasiveness as in claim 4, wherein the step of determining prostasin mRNA levels includes the step of:
applying prostasin-specific oligonucleotide primers in an
RT-PCR to determine the prostasin mRNAlevels in the
sampled human breast carcinoma tissue.
6. The method of determining human breast carcinomas
non-invasiveness as in claim 4, wherein the step of determining prostasin mRNA levels includes the step of:
applying prostasin-specific anti-sense RNA probes in an
in situ hybridization to determine the prostasin mRNA
levels in the sampled human carcinoma tissue.

5

10

15

20

25

30

35

40

45

50

* * * * *

